We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Biotechnology startup Adagio Therapeutics, a spin-out of Adimab, has launched with $50m in Series A funding to support its work on coronavirus antibodies that could prevent and treat Covid-19, as well as any future coronavirus outbreaks.